Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 8/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378863 | 0.86 | PDE3A (0.50) | PDE3APDE3BDGAT1MGAT2MAPT | |
| SCHEMBL2847376 | 0.72 | PDE3A (0.55) | PDE3APDE3BPDE4B | |
| SCHEMBL7380645 | 0.72 | PDE3A (0.54) | PDE3APDE3BALDH1A1SMN1; SMN2GAA | |
| SCHEMBL10764518 | 0.69 | PDE3B (0.56) | PDE3APDE3BMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL10891315 | 0.69 | PDE3B (0.67) | PDE3APDE3BXDHMAPTMEN1 | |
| SCHEMBL16156966 | 0.68 | PDE3B (1.00) | PDE3APDE3BMAPTALDH1A1KDM4E | |
| SCHEMBL16157210 | 0.68 | PDE3B (1.00) | PDE3APDE3BMAPTALDH1A1KDM4E | |
| SCHEMBL20702632 | 0.68 | PDE3B (1.00) | PDE3APDE3BPDE4B | |
| SCHEMBL30692574 | 0.68 | PDE3B (1.00) | PDE3APDE3BPDE4B | |
| SCHEMBL16156997 | 0.68 | PDE3B (1.00) | PDE3APDE3BMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180244629-A1 | Compounds And Compositions For The Treatment Of Cancer | THE BROAD INSTITUTE, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970145-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3A 2661/4885PDE3B 2667/4885DGAT1 2089/4885 |
| US-20180244629-A1 | Compounds And Compositions For The Treatment Of Cancer | TP53, RB1, CDK4 | PDE3A 2661/4885PDE3B 2667/4885DGAT1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.